Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment (Q35558126)

8 August 2017

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment (English)

1 reference

8 August 2017

metastatic breast cancer

1 reference

inferred from title

author

Michelino De Laurentiis

Michelino De Laurentiis

10

0 references

Antonio Giordano

Antonio Giordano

2

0 references

Ugo De Giorgi

5

Ugo De Giorgi

1 reference

8 August 2017

13

Gabriel N Hortobagyi

1 reference

8 August 2017

Massimo Cristofanilli

15

Massimo Cristofanilli

1 reference

8 August 2017

Mario Giuliano

1

1 reference

8 August 2017

Summer Jackson

3

1 reference

8 August 2017

Kenneth R Hess

4

1 reference

8 August 2017

Michal Mego

6

1 reference

8 August 2017

Beverly C Handy

7

1 reference

8 August 2017

Naoto T Ueno

8

1 reference

8 August 2017

Ricardo H Alvarez

9

1 reference

8 August 2017

Sabino De Placido

11

1 reference

8 August 2017

Vicente Valero

12

1 reference

8 August 2017

James M Reuben

14

1 reference

8 August 2017

15 June 2011

1 reference

8 August 2017

Breast Cancer Research

1 reference

8 August 2017

13

1 reference

8 August 2017

3

1 reference

8 August 2017

R67

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr2907

8 August 2017

0 references

cites work

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumour cells in clinical practice: Methods of detection and possible characterization

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Targeted therapy of metastatic breast cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Single agent versus combination chemotherapy for metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Quantifying heterogeneity in a meta-analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218956

Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21699723

12 December 2020

inferred from PubMed ID database lookup

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21699723

12 December 2020

inferred from PubMed ID database lookup

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21699723

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/BCR2907

1 reference

Dimensions Publication ID

8 August 2017

0 references

1 reference

8 August 2017

1 reference